


K. Sandy Pang · A. David Rodrigues ·
Raimund M. Peter
Editors

Enzyme- and Transporter-Based Drug–Drug Interactions

Progress and Future Challenges

 Springer



Editors

K. Sandy Pang
Leslie Dan Faculty of Pharmacy
University of Toronto
144 College Street
Toronto ON M5S 3M2
Canada
ks.pang@utoronto.ca

A. David Rodrigues
Bristol Myers Squibb Co.
P.O.Box 4000
Princeton
NJ 08543
USA
david.rodrigues@bms.com

Raimund M. Peter
AstraZeneca UK
Alderley Park
Macclesfield, Cheshire
United Kingdom SK10 4TF
raimund.peter@astrazeneca.com

ISBN 978-1-4419-0839-1 e-ISBN 978-1-4419-0840-7
DOI 10.1007/978-1-4419-0840-7
Springer New York Dordrecht Heidelberg London

Library of Congress Control Number: 2009938736

© American Association of Pharmaceutical Scientists 2010

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Chapter 24

Clinical Studies of Drug–Drug Interactions: Design and Interpretation

David J. Greenblatt and Lisa L. von Moltke

Abstract The potential importance of drug–drug interaction (DDIs) is increasing as polypharmacy becomes more and more prevalent. In vitro data cannot directly predict clinical DDIs, but may provide a rationale for initiation of human studies to confirm or exclude possible interactions. Clinical DDI studies are designed to determine whether there is a real drug interaction not due to chance, how big the interaction is, and whether the DDI is of clinical importance. Statistical significance is not equivalent to clinical significance, and supplemental pharmacodynamic or clinical outcome information is needed to address the importance of a pharmacokinetic DDI.

24.1 Introduction

Drug–drug interactions (DDIs) have become a topic of substantial scientific and public health concern over the last 20 years. While the clinical phenomenon of DDIs had been recognized for a number of decades, several events in and around the years 1988–1993 brought the topic of DDIs to a position of high attention and priority in the scientific community, as well as in the public arena. During this period, multiple human cytochrome P450 (CYP) isoforms became identified, along with increasing understanding of their substrate and inhibitor specificities, relative quantitative importance in human drug metabolism, and mechanisms of genetic regulation (Clarke, 1998; Smith et al., 1998; b; Venkatakrishnan et al., 2001; Venkatakrishnan et al., 2003). Of particular importance in this context was CYP3A, with its unique hepatic and enteric distribution, and its major contribution to clearance of many clinically relevant drugs as well as naturally occurring chemicals (Venkatakrishnan et al., 2001; Venkatakrishnan et al., 2003; Guengerich,

D.J. Greenblatt (✉)
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine
and Tufts Medical Center, Boston, MA, USA
e-mail: dj.greenblatt@tufts.edu

K.S. Pang et al. (eds.), *Enzyme- and Transporter-Based Drug–Drug Interactions*,
DOI 10.1007/978-1-4419-0840-7_24,

625

© American Association of Pharmaceutical Scientists 2010

1999; Greenblatt et al., 2008). At the same time, *in vitro* techniques for studying human drug metabolism became increasingly developed and refined, including predictive models for *in vitro*–*in vivo* scaling, and the availability of heterologously expressed individual human CYPs. At a clinical level, polypharmacy was becoming increasingly prevalent, as the population aged, the number of patients with multiple illnesses increased, and our capacity to provide pharmacologic treatments for serious disorders became more and more effective. Some newly introduced classes of medications – such as the azole antifungal agents and the selective serotonin reuptake inhibitor (SSRI) antidepressants – offered unique therapeutic options, but also had the secondary property of inhibiting certain human CYPs, thereby elevating the risk of DDIs (Greenblatt et al., 1999; Hemeryck and Belpaire, 2002; Venkatakrishnan et al., 2000). A dramatic and widely publicized event was the interaction of the nonsedating antihistamine terfenadine with potent CYP3A inhibitors such as ketoconazole and erythromycin (Honig et al., 1993b; Honig et al., 1992; Honig et al., 1994; Honig et al., 1993a). Under usual circumstances, terfenadine itself served only as a prodrug, being essentially completely transformed via hepatic and enteric CYP3A into fexofenadine, which was the entity having antihistaminic properties. Although terfenadine had effects on the cardiac QT_c interval (Rampe et al., 1993; Crumb et al., 1995), this was of minimal concern since intact terfenadine does not ordinarily reach the systemic circulation. However, during co-treatment with CYP3A inhibitors, conversion of terfenadine to fexofenadine is blocked, and potentially hazardous levels of the parent drug reach the circulation (Honig et al.,




Fig. 24.1 Number of articles indexed as DDI studies published per year in the Journal of Clinical Pharmacology, 1990–2008

1994; von Moltke et al., 1994b). A few cases of serious and even fatal cardiac arrhythmias were reported as a consequence (Monahan et al., 1990; Woosley et al., 1993). The “terfenadine affair” led to an acutely increased awareness of the potential importance of DDIs. Terfenadine was withdrawn from clinical practice, and a number of regulatory reforms increased the requirements for DDI assessments as a component of drug development. The overall shift in focus of the scientific and drug development community is clearly evident from the prevalence of DDI studies among scientific publications (Fig. 24.1).

24.2 Epidemiology of Drug–Drug Interactions

Given the prevalence of polypharmacy in contemporary clinical practice, the number of *possible* DDIs can become very large. If an individual patient is taking n drugs concurrently, the number of pairwise combinations of these two drugs can be calculated as follows:

$$\frac{n!}{(n-2)!2!} \quad (24.1)$$

The larger the value of n , the greater the number of different drug combination pairs, and potential pairwise DDIs (Table 24.1). A patient with diabetes, hypertension, ischemic heart disease, and depression might well be taking 10 drugs concurrently, in which case the number of possible drug interactions is 45. Considering this large “denominator” of possibilities, the number of clinically important DDIs encountered in contemporary therapeutics actually is relatively small.

Table 24.1 Relation of number of drugs concurrently administered to the number of possible pairwise drug–drug interactions

Number of drugs	Possible pairwise drug interactions
2	1
3	3
4	6
5	10
6	15
7	21
8	28
9	36
10	45
11	55
12	66

The outcome options following concurrent administration of two drugs can be constructed based on a probability hierarchy (Fig. 24.2). The most probable outcome is that the two drugs act independently, with no evidence of any interaction. Less probable is a DDI which can be demonstrated in a controlled laboratory setting, but is not detectable in clinical practice either because the magnitude of the change

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.